Journal article
On-Label Versus Off-Label Use of Recombinant Activated Factor VII: A Comprehensive Review of Use in Two Canadian Centers
Abstract
Recombinant activated factor VII (rFVIIa; NovoSeven, NiaStase, Novo Nordisk, Bagsvaerd, Denmark) was originally developed for the treatment of bleeds in patients with hemophilia and inhibitors. However, the agent is increasingly being employed in "off-label"/unlicensed indications. Consequently there is a need to undertake comprehensive reviews of rFVIIa use; the resulting information will facilitate understanding of how the agent is currently …
Authors
Carcao MD; Webert KE
Journal
Seminars in Hematology, Vol. 45, No. 2 Suppl 1, pp. s68–s71
Publisher
Elsevier
Publication Date
April 2008
DOI
10.1053/j.seminhematol.2008.03.003
ISSN
0037-1963